About Jubilant Life Sciences Ltd.

Overview 

 

Jubilant Life Sciences Limited (formerly Jubilant Organosys) is an Indian pharmaceuticals and life sciences company with its head office in Noida, Uttar Pradesh, India. Founded in 1978, it manufactures and sells Pharmaceuticals and Life Science Ingredients to 100+ countries worldwide, including India (29%) and overseas (71%) such as North America, Europe and Japan.

 

The company operates in the following segments:

  • Pharmaceuticals – comprising 46% of total revenues – such as Generics like Active Pharmaceutical Ingredients (APIs); Solid Dosage Formulations; and Specialty Pharmaceuticals such as Radiopharmaceuticals and Allergy Therapy Products; and Contract Manufacturing Services for sterile injectable and drug discovery solutions.

  • Life Science Ingredients – comprising 54% of total revenues – such as Advance Intermediates & Specialty Ingredients; Life Science Chemicals; and Nutritional Products.

 

As on 31 March 2015, the company had (as per its website):

  • 10 manufacturing facilities (India – 7; North America – 3)

  • 48 subsidiaries

  • 8 R&D locations globally with a 900+ strong R&D team

  • Invested 6% of its annual revenues on R&D

  • The largest integrated facility (463 acres) in the world for Advance Intermediates, Fine Ingredients, Crop Science Ingredients and Life Science Chemicals

 

Global Leadership Position

The company enjoys a global leadership for several products, such as:

  1. Pharmaceuticals

    1. APIs – Globally No.1 in 4 APIs; and among Top 3 in 3 APIs

    2. Generics – No.1 in US in 3 products; and among Top 3 in 5 products

    3. Radiopharmaceuticals – No.1 in North America in 3 nuclear medicine products

    4. Allergy Immunotherapy – Among Top 3 suppliers in North America

  2. Life Science Ingredients

    1. Advance Intermediates – Globally No. 1 in Pyridine & Beta Picoline

    2. Fine Ingredients – Globally No.1 in 11 Pyridine Derivatives

    3. Nutrition Ingredients – Globally No. 2 in Niacin & Niacinamide

 

Jubilant Life Sciences Limited is listed on the National Stock Exchange of India (NSE) and the Bombay Stock Exchange (BSE).

 

Jubilant Life Sciences Limited at-a-glance

  • Employees 6100

  • Turnover (31 March, 2015) ~USD 953 m

  • Markets Served (countries) 100+

  • Manufacturing Facilities 10

  • Key Markets North America

Europe

Japan

India

 

 

 

Approvals

ISO 9001, ISO 14001

OHSAS 18001

US FDA

UK MHRA

ANVISA Brazil

PMDA Japan

AFSSAPS France

 

*Source: http://www.jubl.com/, Corporate Presentation, Annual Report 2014-15

 

 

Milestones

  • 1978 – Incorporated as Vam Organic Chemicals Ltd.

    • 1981 – Starts initial public offering (IPO), and listing on stock exchanges of India

    • 1983 – Commences commercial production of Vinyl Acetate Monomer (VAM)

    • 1985 – Gets formal recognition from the Govt. of India for its R&D Centre

  • 1990 – Commissions first Pyridine & Picoline plant

  • 1995 – Receives ISO 9001 certification

  • 1997 – Commissions first multi-purpose fine chemicals plant

  • 1998

    • Commissions plants for Pyridine HBR and Cyano Pyridine

    • Launches marketing subsidiary in the US

    • Acquires acetyl plant

  • 2000

    • Enters the Bio/chemo informatics via Jubilant Biosys Ltd.

    • Enters high value-added Pyridine Derivates by commissioning Pyridine HBR and Cyano Pyridine plants

    • Launches marketing subsidiary in the US

    • Acquires acetyl plant

  • 2001 – Changes corporate and business profile (Jubilant Organosys Ltd.)

  • 2002 – Acquires API business

  • 2003 – Sets up a new R&D Centre in Noida (Delhi NCR)

  • 2004

    • Enters medicinal chemistry via Jubilant Chemsys Ltd.

    • Sets up a Contract Clinical Research Organisation (Jubilant Clinsys)

    • Enters the formulations and regulatory affairs business by acquiring pharmaceutical companies in Europe (Pharmaceuticals Services Incorporated, N.V. and PSI Supply N.V)

  • 2005

    • Acquires a pharmaceutical company with an FDA-approved manufacturing facility in the US, engaged in off patent drug development and supply

    • Acquires Target Research Associates, Inc. – a US based Clinical Research Organisation (CRO) – and renames it Clinsys Inc.

    • Acquires a generic pharmaceutical company in USA having a US FDA approved formulations manufacturing facility – Trinity Laboratories, Inc. and its subsidiary, Trigen Laboratories, Inc. – and renames it Jubilant Pharmaceuticals, Inc.

  • 2007 – Acquires a US contract manufacturer of sterile injectable vials and allergenic extracts, Hollister Stier Laboratories

  • 2008

    • Forms a Drug Discovery partnership with Amgen Inc., USA

    • Acquires TrialStat ClinicalAnalytics®, an EDC platform

    • Acquires Canadian contract manufacturer of sterile & non-sterile products and radiopharmaceuticals, DRAXIS Specialty Pharmaceuticals, Inc.

    • Acquires fine chemicals manufacturer, Speciality Molecules Pvt. Ltd.

  • 2009

    • Inaugurates Jubilant Kalpataru Hospital at Barasat, Kolkata

    • Extends drug discovery collaboration with Lilly upon successful delivery of prelinical candidates

    • Enters into joint venture for drug discovery with UAB and Southern Research in the US

    • Enters into research collaboration with AstraZeneca for providing new preclinical drug candidates

    • Receives approval for launch of Draximage’s generic Sestamibi in the US and signs exclusive distribution agreement with GE Healthcare

    • Collaborates with Orion for hybrid and integrated drug discovery

    • Receives approval for Sestamibi in Canada

    • Partners in drug discovery with Bioleap

  • 2010

    • Demerges Agri & Performance Polymers business to Jubilant Industries Limited (JIL)

    • Changes name from Jubilant Organosys Limited to Jubilant Life Sciences Limited

    • Strengthens global leadership position in Vitamin B3

  • 2011

    • Receives USFDA approval for Donepezil Hydrochloride tablets (5mg & 10 mg)

    • Sets up global scale capacities for in-house developed Symtet

  • 2012

    • Receives USFDA approval for 4 Dosage Formulations in CVS and CNS

    • Collaborates with Mnemosyne Pharmaceuticals on drug discovery

  • 2013

    • Receives Excellence Award from Export Promotion Bureau

    • Wins Supply Chain Excellence Award at the 7th Express, Logistics & Supply Chain Leadership Awards, 2013

  • 2014

    • Successfully acquires minority shares of Cadista Holdings Inc., which now becomes a wholly-owned subsidiary of Jubilant Life Sciences Limited

    • Wins Excellence Award at India Pharma Awards, 2014

    • Partners with BRI Partners to Bring XylamaxTM to the South Asia Poultry Market

    • Receives the Golden Peacock Business Excellence Award, 2014

    • Announces unique collaborative discovery program with Orion Corporation in Pain Management Area through Jubilant Biosys

    • Extends research for TB Drug Discovery with IDRI through Jubilant Chemsys

    • Declared winner of Bio Excellence Award 2014 at Bangalore India Bio 2014

    • Announces expansion of Drug Discovery Alliance with Janssen Pharmaceutical through Jubilant Biosys

  • 2015

    • Receives Golden Peacock National Quality Award

    • Wins ASSOCHAM’s Responsible Organization Excellence Award, 2014-15

 

BOARD OF DIRECTORS

  • Founder:

  • Chairman: Mr. Shyam S Bhartia

  • Co-Chairman & Managing Director: Mr. Hari S Bhartia

  • Executive Director: Mr. Shyamsundar Bang

  • Directors: Mr. Shardul S Shroff ,   Mr. S. Sridhar,   Mrs. Sudha Pillai,  Dr. Ashok Misra

 

Jubilant Life Sciences Limited Contact Details
 

 

CORPORATE OFFICE

Jubilant Life Sciences Limited

1A, Sector 16A

Noida – 201 301

Uttar Pradesh, India

 

Tel: +91 120 4361000

Fax: +91 120 4234881/84/85/87/95/96

Email: support@jubl.com

Website: http://www.jubl.com/

 

USA OFFICE

Jubilant Hollister Stier LLC

3525, N. Regal, Spokane

Washington-99207, USA

 

Tel: +1 509 489 5656

Fax: +1 509 484 4320

Email: www.hollisterstier.com

 

Jubilant Cadista Pharmaceuticals, Inc

207, Kiley Drive, Salisbury

Maryland-21801, USA

 

Tel: +1 410 860 8500

Fax: +1 410 860 8719

Email: www.cadista.com

 

Jubliant Life Sciences USA Inc.

790 Township Line Road

Suite 175, Yardley

PA 19067, USA

 

el: +1 908 658 9988

Fax: +1 908 658 9927

BELGIUM OFFICE

Jubilant Pharmaceuticals N.V.

Guldensporenparkm Block C-nr. 22, Gelijkvlovers Links, 9820 Merelbeke, Belgium

Tel: +32 9 233 1404

Fax: +32 9 233 0016

strong>CANADA

Jubilant DraxImage, Inc

16751, TransCanada Highway, Kirkland(Montreal), Quebec. Canada H9H 4J4

Tel: +514 630 7080

Fax: +514 694 9295

www.draximage.com

CHINA OFFICE

Jubliant Life Sciences (Shanghai) Ltd.

Room No. 3403, Hong Kong plaza, South Tower, 283, Huai Hai Zhong Road, Shanghai -200021,

China

Tel: +86 21 6390 7388

Fax: +86 21 6390 7399

FOR INVESTORS

Mr. Ravi Agrawal

Jubilant Life Sciences Limited

Tel: +91-120-436 1002

Email: ravi_agrawal@jubl.com

 

Mr. Anupam Jain

Jubilant Life Sciences Limited

Tel: +91-120-436 1021

Email: anupam_jain@jubl.com

 



Comment!
 
 






* Indicates mandatory field.
Please wait while comments are being sent...